Please enable JavaScript.
Coggle requires JavaScript to display documents.
Viral Hepatitis - Coggle Diagram
Viral Hepatitis
Hep B
3% world pop. chronically infected
Chronic hep., cirrhosis (30%), hepatocellular carcinoma (50%)
acute infection: asymptomatic or icteric hepatitis or fulminant (<6months)
chronic infection: healthy carrier or cirrhosis & HCC (>6months)
Transmission: Blood/blood products, Sexual contact, perinatal (depends on viral load in mother 90% transmission by HBeAg + mothers)
Management of Chronic Infection:
Medications
- Interferon Alpha- stimulates immune system to attack the virus/anti viral effect. 1/52 injection x 48 weeks.
- Oral Antiviral agents inhibit viral replication- Entercavir/Tenofovir. May need life long treatment.
Monitoring for liver cancer- ultrasound, alpha feto protein.
Transplant- Fulminant hepatitis, end stage chronic hepatitis
PT. education
-
-
-
Hep. A
-
-
Complications:
Cholestatic hepatitis,
relapsing hepatitis,
fulminant hepatic failure
-
-
-
Hep C
-
-
Transmission: Blood (IVDU accidental needle stick injury), Sexual Transmission, Vertical (high viral load & HIV coinfection)
Treatment: Direct Acting Anti-virals (DAA's) eg. Simeprevir, Sofosbuvir.
Target specific steps in the Hep C lifecycle, shorter duration of treatment, less side effects, high cure rates >90%, expensive
-
Diagnosis: detection of antibodies to Hep C, detection of Hep C antigen, detection of HC RNA in bloodstream
Hep E
RNA virus, incubation period 2-8weeks
Risk Groups: immunosuppressed, travellers
90% pt. will be asymptomatic
Diagnosis: Hep E IgM detectable in serum, Hep E RNA detected in blood
NO treatment, vaccine licensed in china
-
-
-
-
Clinical Findings
Abnormal Liver Function Tests: AST, alanine aminotransferase, bilirubin all increased